Personalized briefing
Discovery of the day · Public Health
Review Duration of New Drugs in the US and European Countries
Dear jacqueline dunbar-jacob, this is your personalized scientific intelligence briefing — curated for your work in Public Health.
Key finding
Medicine · Public Health
Discovery of the day
A cross-sectional study has analyzed the duration of clinical development, regulatory review, and reimbursement review for new drugs in the US, Germany, France, and Switzerland from 2014 to 2024. The researchers examined whether these periods changed over the decade for drugs approved in these countries, providing a comparative assessment of national drug approval timelines. For a nurse and psychologist focused on chronic disease prevention and health behavior, understanding these regulatory and market-access timelines is essential for anticipating when evidence-based pharmacological interventions for conditions like diabetes and cardiovascular disease become available in clinical practice.
Novelty
72%
Rigor
85%
Significance
68%
Validity
82%
Clarity
79%
Advertisement
ScientificChina — The Global Marketplace for Scientific and Medical Equipments Start Browsing →
Your briefing is personalized based on your selected fields, keywords, and research interests.
